NEWARK, Calif., Feb. 01, 2017 (GLOBE NEWSWIRE) — Cymabay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet need, today announced that it intends to offer and sell shares of its Common Stock, subject to market and other conditions, in an underwritten public Offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar and for working capital and general corporate […]
This post first appeared on Bloggerwave Inc. Is In The StockGuru Spotlight For October 22, 2010 | StockGuru SmallCap Alerts On Penny Stocks, please read the originial post: here